---
title: Targeting the TNF/IAP pathway synergizes with anti-CD3 immunotherapy in T-Cell
  Acute Lymphoblastic Leukemia
date: '2024-03-04'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38437728/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20240305170531&v=2.18.0.post9+e462414
source: Blood
description: T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematological
  malignancy. Current treatments, based on intensive chemotherapy regimens provide
  overall survival rates of ~85% in children and <50% in adults, calling the search
  of new therapeutic options. We previously reported that targeting the T cell receptor
  (TCR) in T-ALL with anti-CD3 (CD3) mAbs enforces a molecular program akin to thymic
  negative selection, a major developmental checkpoint in normal T-cell development,
  ...
disable_comments: true
---
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematological malignancy. Current treatments, based on intensive chemotherapy regimens provide overall survival rates of ~85% in children and <50% in adults, calling the search of new therapeutic options. We previously reported that targeting the T cell receptor (TCR) in T-ALL with anti-CD3 (CD3) mAbs enforces a molecular program akin to thymic negative selection, a major developmental checkpoint in normal T-cell development, ...